Chronic Obstructive Pulmonary Disease
Conditions
Brief summary
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Detailed description
This is a non-randomized, non-interventional study that is part of the RCT DUPLICATE initiative (www.rctduplicate.org) of the Brigham and Women's Hospital, Harvard Medical School. It is intended to replicate, as closely as is possible in healthcare insurance claims data, the trial listed below/above. Although many features of the trial cannot be directly replicated in healthcare claims, key design features, including outcomes, exposures, and inclusion/exclusion criteria, were selected to proxy those features from the trial. Randomization is also not replicable in healthcare claims data but was proxied through a statistical balancing of measured covariates according to standard practice. Investigators assume that the RCT provides the reference standard treatment effect estimate and that failure to replicate RCT findings is indicative of the inadequacy of the healthcare claims data for replication for a range of possible reasons and does not provide information on the validity of the original RCT finding.
Interventions
DRUGTiotropium
Tiotropium dispensing claim is used as the reference group.
Salmeterol/Fluticasone dispensing claim is used as the exposure group.
Sponsors
Brigham and Women's Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Age between 40-80 years \[0,0\] days * Diagnosis of COPD \[all available data, 0\] days * Clinical history of at least 1 COPD exacerbation \[all available data, -43\] days
Exclusion criteria
* COPD exacerbation \[-42, 0\] days * Asthma, eczema, atopic dermatitis, allergic rhinitis \[-180, 0\] days * Known respiratory disorder other than COPD e.g. pulmonary fibrosis or interstitial lung disease (ILD), sarcoidosis, lymphangioleiomyomatosis, primary/pulmonary tuberculosis, cystic fibrosis, pulmonary hypertension/other pulmonary heart disease, lung/pulmonary malignancies, alpha-1 antitrypsin deficiency, pneumoconioses and other lung diseases due to external agents \[all available data, 0\] days * Narrow angle glaucoma or prostatic hyperplasia or obstruction of the neck of the bladder \[-180, 0\] days * At least one 30-day supply prescription claims for oral alfuzosin, doxazosin, tamsulosin, silodosin, finasteride 5 mg, dutasteride \[-180,0\] days * Lung transplant or lung volume reduction surgery (LVRS) \[all available data, 0\] days * Daily long term oxygen therapy (LTOT) \[all available data, 0\] days * Beta-blockers (except eye drops) \[-180, 0\] days * Evidence of alcohol, drug or solvent abuse \[-180, 0\] days * Use of salmeterol, tiotropium and fluticasone containing inhaler use \[-180, 0\] days
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Healthcare utilization exacerbation rate per year | Through study completion or censoring, up to 193 days | Claims-based algorithm: healthcare utilization exacerbation rate per year |
Countries
United States
Outcome results
None listed